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 ABSTRACT 
Objective: Individual cardiovascular disease (CVD) risk factors are associated with dementia. 
For the first time, we investigated whether the Framingham CVD risk score – which comprises 
these multiple risk factors – was also associated with future dementia risk. 
Methods: Individual participant meta-analysis of two large, general population cohort studies 
(N=11,887). For the purposes of comparison of the dementia results, we also examined the 
association between the Framingham CVD risk score and CVD-related death.  
Results: Framingham CVD risk score was associated with dementia death (HR per 10% 
increased risk, 95%CI: 4.00, 2.44-6.56). Adjusting for age eliminated this association (1.04, 0.53-
2.01); similarly, age explained 88% of the ability of the Framingham CVD risk score to predict 
CVD death.  
Conclusions: The Framingham CVD risk score was no more strongly associated with future 
dementia than age. It therefore offers no added value in predicting dementia.  
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Introduction 
Cardiovascular disease (CVD) and dementia represent a major disease burden worldwide. These 
conditions share a series of risk factors (hypertension, smoking, obesity, diabetes, and 
dyslipidaemia).1 CVD itself, particularly multiple strokes, also appears to elevate dementia risk.2 
The Framingham Cardiovascular Disease Risk Score,3 which comprises these risk factors, is a 
standard tool for assessing future risk of CVD in people who are apparently healthy. This raises 
the possibility that this risk score might also be useful in identifying people at increased risk of 
developing dementia. Since the Framingham CVD risk score is already commonly used in clinical 
practice, the implications of such an observation would be considerable.  
 
While the Framingham CVD risk score has been shown to predict cognitive decline,4 an aspect 
of dementia, to the best of our knowledge, there are no prospective studies examining the links 
between the Framingham CVD risk score and future dementia.5 Accordingly, we meta-analysed 
individual-participant data from two large English population-based cohort studies.  
 
Methods 
Participants were taken from the Health Survey for England,6 a series of annual, on-going, 
independent, general population-based cross-sectional studies that are representative of 
household-dwelling individuals in England in most years. Participants gave informed consent 
and ethical approval was obtained from the London Research Ethics Council.  
 
The scientific focus of each survey changes year to year; risk factor data for calculating the 
Framingham CVD risk score3 (age, sex, HDL-cholesterol, total cholesterol, systolic blood 
pressure, smoking, and diabetes) were available for surveys conducted in 1998 and 2003. 
Mortality follow-up of study members in these studies continued until death or 15th February 
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2008, whichever came first. Dementia- and CVD-related deaths3 were identified from any 
mention on death certificates of the following codes: dementia – ICD-9 codes 290.0-290.4 
(senile dementia, uncomplicated; presenile dementia; senile dementia with delusional or 
depressive features; senile dementia with delirium; or vascular dementia), 294.9 (unspecified 
persistent mental disorders due to conditions classified elsewhere), 331.0-331.2 (Alzheimer’s 
disease; frontotemporal dementia; or senile degeneration of the brain), and 331.9 (cerebral 
degeneration, unspecified) and ICD-10 codes F01, F03, F09, G30, and G31; CVD – ICD-9 
codes 410-414 (ischaemic heart disease), 428 (heart failure), 430-438 (cerebrovascular disease), 
440 (atherosclerosis), and 443-445 (other peripheral vascular disease; arterial embolism and 
thrombosis; or atheroembolism) and ICD-10 codes I20-I25, I50, I60-I69, I70, I73, and I74. 
 
Using similar methodology to previous studies,7 we used Cox proportional hazards models to 
compute study-specific effect estimates with accompanying standard errors which we pooled in a 
random effects meta-analysis. We report unadjusted hazard ratios (HR) with accompanying 95% 
confidence intervals (CI) per 10% increase (disadvantage) in the Framingham CVD risk score in 
relation to dementia-related deaths following the convention in testing multifactorial predictive 
algorithms8. Models were also adjusted for age and sex. We also ran models examining the 
association between the Framingham CVD risk score and CVD-related death to compare the 
predictive utility of the score for dementia with its original purpose.  
 
In addition, we conducted a number of supplementary analyses: including only individuals aged 
<75 years since the Framingham CVD risk score is recommended for use in this age-group; 
using the Framingham CVD risk score having substituted BMI for HDL- and total cholesterol;3 
and dropping any dementia-related deaths during the first two years of follow-up in order to 
assess reverse causality (49 dementia deaths). In a further sensitivity analysis, missing values for 
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covariates were imputed with PASW statistics version 18.0 using five imputations. All other 
statistical analyses were conducted using R version 2.15.0.  
 
Results 
From an initial sample of 21,945 participants, 1,997 did not consent to record linkage and 6,071 
had missing data. Additionally, we excluded 1,990 with evidence of CVD at baseline. These 
exclusions resulted in an analytic sample of 11,887 (mean[SD] age 54.0[13.2] years, range=35-95). 
Individuals with missing data (N=6,056) were slightly older (55.2[SD=14.4] vs 54.0[13.2], 
p<0.001) and somewhat more likely to be female (58.9% female vs 54.4%, p<0.001), the 
statistically significant differences arising from a large sample size rather than any sizeable 
absolute differences.  
 
Of the 875 deaths during a mean (SD) follow up of 7.1 (2.6) years, 54 were dementia-related (13 
Alzheimer disease, two vascular dementia, and 39 dementia sub-type not specified). The Figure 
shows the relation of the Framingham CVD risk score with deaths from dementia and CVD. 
Higher Framingham CVD risk score was associated with increased risk of dementia death: each 
10% increase (disadvantage) was associated with a 4.00-fold (95%CI 2.44-6.56) increase in the 
risk of dementia death (ptrend<0.001). Adjusting for sex increased the magnitude of the association 
(HR 5.08; 3.50-7.37; ptrend<0.001). Age is part of the Framingham CVD risk score algorithm, but 
because dementia is age-related (HR per year increase: 1.21; 1.17-1.24) we additionally controlled 
for age in these analyses whereupon the association between the Framingham CVD risk score 
and dementia was eliminated (age-adjusted HR 1.04; 0.53-2.01; ptrend=0.91).  
 
Using CVD-related death as the outcome of interest also showed a substantial attenuation of the 
relationship after age-adjustment although, unlike dementia, there was still evidence of increased 
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CVD risk. Thus, a higher Framingham CVD risk score was associated with 3.76-fold (95%CI 
2.63-5.39; ptrend<0.001) increased risk of CVD death per 10% increase in Framingham CVD risk 
score before, and 1.34-fold (0.73-2.45; ptrend=0.34) risk after, age-adjustment.  
 
None of the supplementary analyses, mentioned above, altered our conclusions. Restricting the 
models to individuals aged <75 years (N=10,828; 12 dementia deaths, 128 CVD deaths) gave an 
unadjusted HR for dementia death of 3.96 (95%CI 0.92-16.99, ptrend=0.064) and an age-adjusted 
HR of 0.96 (0.04-22.2, ptrend=0.98). The unadjusted HR for the association between the 
Framingham CVD risk score-BMI and dementia death (N=14,148; 53 dementia deaths) was 3.23 
(95%CI 1.08-9.71; ptrend<0.001). Dropping any deaths during the first two years of follow-up (49 
dementia deaths) resulted in an unadjusted HR for dementia death of 2.34 (95%CI 0.46-11.84; 
ptrend=0.30) and an age-adjusted HR of 0.37 (0.01-9.78; ptrend=0.55). 
 
Accounting for missing data by multiple imputation did not appreciably change the results: 
association between the Framingham CVD risk score and dementia death, unadjusted HR 3.63 
(95%CI 2.78-4.73; ptrend<0.001), age-adjusted HR 1.13 (0.83-1.53; ptrend=0.45); association between 
the Framingham CVD risk score and CVD death, unadjusted HR 3.47 (2.93-4.11; ptrend<0.001), 
age-adjusted HR 1.34 (1.05-1.71; ptrend=0.017). 
 
Discussion 
The aim of the present analyses was to examine whether the Framingham CVD risk score was 
useful in predicting future risk of dementia. In a large population sample of adults who were free 
from CVD at study induction, we found an association between elevated Framingham CVD risk 
score and an increased risk of dementia death that was greater in magnitude than the relationship 
between Framingham CVD risk score and CVD-related death. However, the Framingham CVD 
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risk score-dementia relation was lost when age was added to the multivariable model. While age 
also explained 88% of the ability of the Framingham CVD risk score to predict CVD it did not 
completely remove the association. 
 
As described, there is evidence of an association between the Framingham CVD risk score and 
cognitive decline.4 To our knowledge, this is the first large-scale prospective population-based 
study to examine the association between the Framingham CVD risk score and dementia, and 
certainly the first to use individual participant meta-analysis methodology.  
 
Any mention of dementia on a death certificate resulted in a death being classified as dementia-
related. This is appropriate as dementia may well not be the immediate cause of death but an 
important contributory factor. Classifying cause of death according to death certification is a 
common methodology in population-based studies. Under-reporting of dementia on death 
certificates seems to be improving—a recent memory clinic study found that 71.5% of 502 
patients with probable Alzheimer disease had dementia correctly recorded on their death 
certificates.9 Autopsy studies confirm that death certification of CVD is satisfactory for the 
purposes of epidemiological research.10  
 
None of the additional analyses essentially altered the findings of the study. However, dropping 
dementia-related deaths in the first two years of follow up did reduce the magnitude of the 
association between the Framingham CVD risk score and dementia death suggesting that part of 
the observed association between the risk score and dementia may relate to participants suffering 
from undiagnosed subclinical CVD at baseline. Approximately a third of participants (33.8%) 
had data missing for one or more variable necessary for calculating the Framingham CVD risk 
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score. However, accounting for missing data by multiple imputation had little effect on the 
results and therefore the missing data are unlikely to have resulted in bias. 
 
While cardiovascular disease risk factors have been linked to cognitive decline4 and dementia 
risk,1 these results suggest that, importantly, the Framingham CVD risk score was no more 
strongly associated with future dementia than age. It therefore offers no added value in 
predicting dementia. Therefore, though CVD risk factors may play a role in dementia aetiology, 
future research attention should also focus on non-CVD risk factors and risk markers for 
dementia, including changes in A 42 levels in cerebrospinal fluid,11 metabolic alterations in PET 
scans,12 and possibly also biomarkers related to immune function, endocytosis and amyloid-  
precursor proteins.13-15 
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Table 1. Characteristics of the 1998 and 2003 Health Surveys for England 
 1998 2003 Total 
N (complete data for all variables) 6656 5321 11887 
Participants with missing data (%) 2721 (29.0) 3335 (38.9) 6056 (33.8) 
Age  (mean [SD]) 
range 
54.0 (13.4) 
35-95 
54.0 (12.9) 
35-94 
54.0 (13.2) 
35-95 
Female (%) 53.9 55.1 54.4 
Years of follow-up (mean [SD]) 9.1 (1.6) 4.5 (0.5) 7.1 (2.6) 
Number of deaths 713 162 875 
Dementia deaths 50 4 54 
Cardiovascular disease deaths 252 49 301 
Ischaemic heart disease deaths 134 27 161 
Cerebrovascular disease deaths 82 19 101 
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Figure 1. Association of Framingham CVD Risk Score with Dementia1 and CVD2 Death 
over a Mean 7.1-year Follow-up 
Hazard ratios (95% confidence intervals) are per 10% increase (disadvantage) in the Framingham 
CVD risk score in men and women who were free from dementia and CVD at baseline in the 
1998 and 2003 Health Surveys for England (N = 11,887).  
 
 
 
 
 
 
 
 
 
 
